Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014–2019

Abstract

Our study demonstrates a shift in antidiabetic medication class utilization from 2014 to 2019, where associated costs net of rebates significantly increased to a disproportionately greater extent than the significant increase in utilization PUPM.